The Low-Risk TAVR trial, the first of its kind, sends “a strong signal” that it is safe to expand transcatheter aortic valve replacement (TAVR) to patients with symptomatic severe aortic stenosis who are at low risk for surgical mortality. Top-line results from LRT showed zero all-cause mortality and zero disabling stroke at 30 days in 200 low-risk patients who underwent TAVR. Watch Drs. Satler and Waksman discuss the results on CardioTube.